Form 4: Xilio Therapeutics Chief Medical Officer Katarina Luptakova Acquires Stock Options

Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, acquired stock options for 59,333 shares of common stock on May 1, 2024.

Summary

• On May 1, 2024, Katarina Luptakova, the Chief Medical Officer of Xilio Therapeutics, acquired stock options.
• The stock options grant her the right to buy 59,333 shares of Xilio Therapeutics common stock at an exercise price of $1.08 per share.
• The options vest monthly starting June 1, 2024, and continuing until May 1, 2028.
• The options expire on April 30, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a key executive is a common practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of these options, typically over a period of 4 years, is also consistent with industry norms.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates